Protocol Ledger

NCT03516084 · Phase III · TERMINATED

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT03516084 sponsored by Zai Lab (Shanghai) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-20 Enrollment: 185 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03516084
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)185 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03516084
Protocol FieldVerified Registry Value
NCT IdentifierNCT03516084
Consolidated Lead SponsorZai Lab (Shanghai) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment185 participants (ACTUAL)
Registered Start Date2018-08-20
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI